Navigation Links
Second in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... forma net operating loss of $1.3 million for the second quarter compared to pro forma net operating ... amortizing the license fee into revenue in the second quarter. Isis received a $375,000 ... Net loss from continuing operations for the second quarter of 2009 was $3.8 million compared to net ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for ... loss of $33.4 million or $0.36 per share in the second quarter of 2008. Nektar made ... expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... Assuming positive results in November from our second Phase 3 trial of BENLYSTA, we and GSK plan to ... belimumab can reduce SLE disease activity, and a second Phase 3 trial, BLISS-76, is underway to confirm ... in systemic lupus erythematosus; results of the second BENLYSTA Phase 3 trial are expected in November ...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... risk of dementia associated with PTSD. A second study suggests lower Alzheimer's risk among ... and had the fastest rate of decline. A second study in post-menopausal women found that ... participants for clinical studies is the second greatest barrier to developing better treatments ...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

... Preliminary top-line results of second Phase III study show highly significant decreases ... positive preliminary top-line results from the second of two Phase III clinical trials of sodium ... impact on patients' quality of life." The second 14-week Phase III trial, conducted in the United ...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

... Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug ... treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in ... postulated to have the greatest impact on HCV second phase inhibition, leading us to evaluate CTS-1027 ...

Gene Findings Unlocking Reasons for Neuroblastoma Risk

... to a high-risk form of neuroblastoma. A second genome-wide study found that a copy number ... or early childhood development. Maris's second study, spearheaded by Dr. Sharon Diskin, also of ... is among the largest in the country, ranking second in National Institutes of Health funding. In ...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

... progression free rate supports advancement into second stage of Simon 2-Stage designed trial - ... met the efficacy criteria for advancement to the second stage of enrollment. To date, 29 patients have ... the Phase II trial will now advance to the second stage and enroll a total of approximately 25 ...

Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

... Plans Jazz Pharmaceuticals has completed its second Phase III clinical trial of JZP-6 and expects to ... mid-2009. Assuming positive results for the second study, the company anticipates submitting a New ... including the timing of results from the second Phase III pivotal clinical trial and the ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... anticipate patient enrollment to commence in the second half of 2009." About orBec (R) Two ... the Fred Hutchinson Cancer Research Center. The second trial was a 129-patient pivotal Phase 3 ... trial of DOR201 in radiation enteritis in the second half of 2009. orBec(R) is also currently the ...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... and evaluated and then the study is expanded to a second larger cohort of patients if pre-specified ... the criteria for expanding enrollment to the second cohort. Enrollment of the expanded cohort is now ... on the entire clinical study populations in the second half of 2009." About Phosphatidylserine ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

... cancer. Cervical cancer is the world's second most commonly diagnosed women's cancer, and the second most common cause of cancer death in women.(1) ... globally each year, cervical cancer is the second most common cancer diagnosed among women ...

Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)

... rather than the patient coming back for a second endoscopic and/or surgical procedure. ... the ileo-cecal valve in 44 minutes. A second pan-endoscopy was completed in two procedures by ... approach and the maximum depth was marked. The second procedure was performed on the same patient at a ...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

... Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the ... when used alone, and now we have evidence from a second study that Clonicel also has a complementary ... current study of 200 children with ADHD is the second phase 3 trial in a year to investigate the safety ...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

... upcoming EASL meeting. Pharmasset's unpartnered second generation HCV nucleoside, PSI-7851, is ... expect to report the first antiviral data in the second half of 2009. In addition, we are collecting ... Phase 2 clinical trial. PSI-7851, an unpartnered second generation HCV nucleotide analogue recently ...

Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis

... regimen that helps to prolong life." The second component of the trial will examine the safety of ... been approved to improve lung hydration. A second Phase III clinical trial is actively recruiting ... Argentina, Germany, Belgium and France. This second trial has been designed with the assistance of ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... that it has completed enrollment in the Company's second pivotal Phase 3 clinical trial of Ophena(TM) ... dose of either Ophena(TM) or placebo in the second Phase 3 clinical trial. Due to the high level of ... dryness and dyspareunia. The study is the second pivotal Phase 3 clinical trial for Ophena(TM) , ...

Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)

... study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor ... for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered ... the first antiviral data with PSI-7851 in the second half of 2009." About PSI-7851 PSI-7851 ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical trial will enroll ... support. The first patient was enrolled into the second stage of the ABSORB clinical trial at Onze Lieve ... have been eager to enroll their patients into the second stage of the trial," said John Ormiston, M.D., ...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

... 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 ... data were positive. We will have results of the second Albuferon Phase 3 trial in March 2009, and the ... License Application (BLA) with the FDA in the second quarter of 2009. HGS will receive an additional ...

Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia

... ) today announced completion of enrollment in the second of two Phase III pivotal clinical trials of JZP-6 ... "Completion of enrollment in this second trial is a meaningful milestone in the JZP-6 ... results were announced in November 2008. The second Phase III study has enrolled 575 patients at ...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... Amigal to Initiate Phase 3 Global Development in second Quarter; Continued Strong Financial Position ... Amigal for the treatment of Fabry disease in the second quarter of 2009. Amicus also reviewed data on the ... Amicus continued discussions with the FDA in the second half of 2008. The Agency has indicated that it ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... C. We will have the results of Albuferon's second Phase 3 trial in March. Assuming the second trial is also successful, we expect that global ... Biologics License Application with the FDA in the second quarter. Darapladib: GSK Phase ...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

... Kidney transplantation to be Quark's second indication with clinical-stage, systemically ... kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically ... patients at high risk to develop DGF. The second part of the study will evaluate safety and ...

Pharmasset Reports Fiscal Year End 2008 Financial Results

... 2008, Pharmasset nominated PSI-7851 as its lead, second generation nucleotide candidate for HCV. ... 2009 -- Report phase 1 data with PSI-7851 in second half of 2009 About Pharmasset ... Pharmasset also anticipates filing an IND for its second generation nucleotide inhibitor for HCV, PSI-7851 ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... percent of patients in the VcD arm required a second ASCT, compared with 47 percent of patients ... and days 9 through 12 during only the first and second cycles. Patients in the VAD arm received ... 12 and 17 through 20 during only the first and second cycles. Superior Complete Response Rate ...

Brain Waves Show Sound Processing Abnormalities in Autistic Children

... Dr. Roberts said. "We see a fraction of a second delay in autistic patients." Autism is a ... children with autism there was a fraction of a second delay in the brain's response while processing ... processing system is delayed a fraction of a second in children with autism. Autism ...

Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia

... Phase III clinical trial program also includes a second randomized, double blind, placebo-controlled ... 90% of the subjects have been enrolled in this second Phase III trial. Jazz Pharmaceuticals anticipates ... trials for its product candidates, including the second Phase III clinical trial of the sodium oxybate ...

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

... all four serotypes of dengue one month after the second injection (Day 56), and were highly protected ... all four serotypes of dengue one month after the second injection (Day 56), and were partially protected ... often occurs in children infected for a second time (with a different serotype of dengue), and ...

Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD

... dose of VYVANSE the first week and placebo the second week. The second group received placebo the first week and their optimal dose of VYVANSE the second week. The primary objective of this study was ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

... trial, expected by mid-2009 - - Data from second Phase 3 trial, BLISS-76, expected by fall 2009 - ... enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials ... Phase 3 trial by mid-2009, and data from our second Phase 3 trial by fall 2009. Assuming positive ...

Cardium Reports on Second Quarter 2008 Highlights and Financial Results

... as well as financial results for its second quarter ended June 30, 2008. (Logo: ... depreciation and amortization for the second quarter of fiscal 2008 totaled $943,000. Total revenue for the second quarter 2008 was $627,000, compared to $229,000 ...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... advanced breast cancer. The new trial is the second Phase II study evaluating bavituximab in advanced ... endpoint needed to expand the trial to the second stage. Seven of the 14 evaluable ... most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... today announced financial results for the second quarter of 2008. On a reported basis calculated ... securities totaled $145.0 million. "The second quarter of 2008 was significant for Amicus. We ... President and CEO of Amicus Therapeutics. "In the second half of 2008, we will be focused on finalizing ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... trial, and have initiated dosing of our second AZ-004 Phase 3 clinical trial. In addition, we ... this trial before the end of September 2008. A second Phase 3 clinical trial was initiated in July 2008 ... an end of Phase 2 meeting with the FDA during the second quarter of 2008 and has been granted this meeting ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... plan to initiate by the end of this year, and the second late-stage study of mipomersen, a ... for this indication is anticipated during the second half of 2010. Genzyme and Isis plan to begin ... LDL cholesterol in high-risk patients during the second half of 2008. These trials will include: one ...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

... today reported its financial results for the second quarter of 2008 and updated clinical progress of ... Significant one time transactions during the second quarter of 2008 included the sale of the rights ... and investments to fund operations during the second half of 2008. The Company expects to end 2008 ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... ALXA ) announced today that it has initiated its second Phase 3 clinical trial with AZ-004 (Staccato(R) ... our AZ-004 NDA plan with the start of the second Phase 3 clinical trial this year. We look forward ... sales and marketing of AZ-004." AZ-004 second Phase 3 Clinical Trial Design ...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

... - second instance where survival increase is observed in ... for patients receiving Tavocept. This is the second Tavocept clinical trial where this pattern ... from the Japan Tavocept Trial, and represent the second time we have seen this type of a survival ...

AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer's Vaccine

... already begun for the clinical trial of a second Alzheimer's vaccine by AFFiRiS. Vienna-based ... to offer participation in clinical testing of our second Alzheimer's vaccine, AFFITOPE AD02. The support ... treatment, Alzheimer's is one such disease. The second disease that AFFiRiS has chosen to tackle ...
Other Contents
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics ... has been selected by next-generation sequencing company PrimBio ... whole exome and targeted gene panel interpretation. ... has adopted the most current technologies to support the ... research. The company offers two types of exome sequencing ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
(Date:3/31/2015)... 2015 Bon Secours New York Health ... Schervier Nursing Care Center family last week. The Sisters ... in Yonkers which is scheduled to close later this ... of the Sisters of Charity of New York, the ... to place their Sisters at Schervier Nursing Care Center ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Cosmetic Town, ... the Internet, is proudly enduring adding news to its ... and the consumers of plastic surgery and cosmetic medicine ... user-friendly pages and interconnected sections, the Cosmetic Town community ... addition to the Cosmetic Town site navigation, News and ...
(Date:3/31/2015)... 31, 2015 Karen A. Daley, Ph.D. ... Rivier University’s Commencement ceremony on May 9, ... letters in recognition of her eminent career as a ... a front-line caregiver and senior staff nurse at Brigham ... advancing to leadership roles, including President of the American ...
(Date:3/31/2015)... Indosoft, developer of the Q-Suite call center software suite, announces ... 5.x line. The industry leading contact center ACD ... for more than a decade. By announcing an end of ... fully embrace newer Asterisk features and improve performance. , Q-Suite ... more than a decade. The use of Asterisk, a free, ...
(Date:3/31/2015)... Clinovo, a leading provider of cloud-based ... the premiere voice of Northern California’s Life Science ... , BayBio brings together the collective strength ... productive life science cluster, helping companies grow, connect ... pressing challenges. , “We are thrilled to ...
Breaking Medicine News(10 mins):Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2
Other TagsOther Tags